Search results for "Anti-ulcer Agent"

showing 10 items of 18 documents

A Comparison of Five Maintenance Therapies for Reflux Esophagitis

1995

Patients with reflux esophagitis have a high rate of relapse within one year after therapy is discontinued.We enrolled 175 adults with endoscopy-confirmed reflux esophagitis in a prospective study comparing five maintenance therapies. All the patients were initially treated with omeprazole (40 mg orally once a day) for four to eight weeks, and healing was confirmed by endoscopy. Participants were then stratified according to their initial grade of esophagitis and randomly assigned to 12 months of treatment with one of the following: cisapride (10 mg three times a day), ranitidine (150 mg three times a day), omeprazole (20 mg per day), ranitidine plus cisapride (10 mg three times a day), or …

AdultMalemedicine.medical_specialtyRanitidineSeverity of Illness IndexGastroenterologyDisease-Free SurvivalRanitidinePiperidinesRecurrenceInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesReflux esophagitisProspective cohort studyEsophagitis PepticOmeprazoleCisapridemedicine.diagnostic_testEsophageal diseasebusiness.industryGeneral MedicineMiddle AgedAnti-Ulcer Agentsmedicine.diseaseSurgeryEndoscopyTreatment OutcomeHistamine H2 AntagonistsCisaprideDrug Therapy CombinationFemaleEsophagoscopybusinessEsophagitisOmeprazolemedicine.drugNew England Journal of Medicine
researchProduct

Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics

1997

AdultMalemedicine.medical_specialtyglossitiGlossitismedicine.drug_classAntibioticsadverse drug reactionLansoprazole2-PyridinylmethylsulfinylbenzimidazolesGlossitisPharmacotherapyTongueClarithromycinClarithromycinmedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)StomatitisAgedStomatitisbusiness.industryMiddle AgedAnti-Ulcer Agentsmedicine.diseaselansoprazoleDermatologyAnti-Bacterial Agentsmedicine.anatomical_structureDrug Therapy CombinationFemalebusinessclarythromicinOmeprazoleAdverse drug reactionmedicine.drug
researchProduct

Effect of intravenous application of esomeprazole 40???mg versus pantoprazole 40???mg on 24-hour intragastric pH in healthy adults

2007

BACKGROUND: It has been demonstrated that therapy with proton pump inhibitors reduces recurrence of bleeding following initial endoscopic treatment of bleeding peptic ulcers. AIM: This study compared the effects of esomeprazole 40 mg and pantoprazole 40 mg on intragastric acid control. Both substances were administered intravenously as 15-min infusion and as bolus injection. METHODS: Healthy men and women volunteers were enrolled in this single-center, open, randomized, three-way crossover study. After administration of esomeprazole 40 mg and pantoprazole 40 mg intravenously as 15-min infusion, and pantoprazole 40 mg intravenously as bolus injection, continuous 24-h intragastric pH monitori…

AdultMalemedicine.medical_specialtymedicine.drug_classPepticProton-pump inhibitorPharmacologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesHelicobacter InfectionsEsomeprazoleGastric AcidInternal medicineHumansMedicineEsomeprazole SodiumInfusions IntravenousPantoprazoleMonitoring PhysiologicPantoprazoleCross-Over StudiesHelicobacter pyloriHepatologybusiness.industryStomachGastroenterologyEsomeprazoleGastric Acidity DeterminationHydrogen-Ion ConcentrationMiddle AgedAnti-Ulcer AgentsCrossover studymedicine.anatomical_structureInjections IntravenousBody ConstitutionGastric acidFemalebusinessmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

2001

Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.

DrugPeptic Ulcermedicine.drug_classmedia_common.quotation_subjectProton-pump inhibitorPharmacologyEsomeprazolelaw.inventionZollinger-Ellison SyndromelawmedicineHumansDrug InteractionsOmeprazoleRandomized Controlled Trials as Topicmedia_commonClinical pharmacologyHepatologybusiness.industryGastroenterologyEsomeprazoleProton Pump InhibitorsAnti-Ulcer AgentsBioavailabilityProton pumpSafety profilebusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct

Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study

2003

Abstract Background. Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category. This might be useful to reduce the duration of anti-Helicobacter therapies. Aims. The aim of this study was to assess whether there is the possibility of shortening a rabeprazole-based triple therapy from 7 to 4 days without compromising its efficacy in the eradication of Helicobacter pylori infection. Patients. A total of 128 consecutive dyspeptic patients with H. pylori infection were recruited for this controlled, randomized, open and parallel-group trial comparing the efficacy of two durations of the same rabeprazole-based tr…

MalePeptic Ulcermedicine.medical_specialtymedicine.drug_classUrea breath testRabeprazoleProton-pump inhibitorPilot ProjectsGastroenterology2-PyridinylmethylsulfinylbenzimidazolesDrug Administration ScheduleHelicobacter InfectionsAnti-Infective AgentsClarithromycinMetronidazoleClarithromycinInternal medicinemedicineHumansProspective StudiesDyspepsiaAdverse effectHelicobacter pyloriHepatologybiologymedicine.diagnostic_testbusiness.industryGastroenterologyProton Pump InhibitorsMiddle AgedHelicobacter pyloriAnti-Ulcer Agentsbiology.organism_classificationAnti-Bacterial AgentsMetronidazoleRegimenTreatment OutcomeRabeprazoleBenzimidazolesDrug Therapy CombinationFemalebusinessOmeprazolemedicine.drug
researchProduct

Antiulcer activity of Cyperus alternifolius in relation to its UPLC-MS metabolite fingerprint: A mechanistic study

2019

Abstract Background Gastric ulcer is one of the main prevalent gastrointestinal multi-etiological disorders with many associated complications and adverse effects. Our aim was to develop safer antiulcer therapies based on methanol or ethyl acetate extracts of tubers and aerial parts from Cyperus alternifolius. Methods Gastric ulceration was experimentally generated by administration of single oral doses of indomethacin (30 mg/kg) to fasted rats. The animals received methanol or ethyl acetate extracts of C. alternifolius tuber and methanol or ethyl acetate extracts of aerial parts at two dose levels (50 or 100 mg/kg). Ranitidine (50 mg/kg) was used as standard anti-ulcer drug. After 4 h, the…

Malemedicine.drug_classAntiulcer drugMetaboliteIndomethacinPhytochemicalsAnti-Inflammatory AgentsEthyl acetatePharmaceutical ScienceAcetatesAnti-inflammatoryRanitidine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTandem Mass SpectrometryDrug DiscoverymedicineMetabolomeAnimalsMetabolomicsStomach UlcerCyperusRats WistarAcetic Acid030304 developmental biologyPharmacology0303 health sciencesTraditional medicinebiologyPlant ExtractsChemistryMethanolPlant Components AerialAnti-Ulcer Agentsbiology.organism_classificationRatsCyperus alternifoliusPlant TubersComplementary and alternative medicinePhytochemicalGastric Mucosa030220 oncology & carcinogenesisMetabolomeMolecular MedicineChromatography Liquidmedicine.drugPhytomedicine
researchProduct

Effects of zinc acexamate on blood flow and prostanoid levels in the gastric mucosa of the rat

1989

The effects of the new antiulcer compound zinc acexamate on blood flow and prostanoid levels in the gastric mucosa have been studied. Zinc acexamate (30 and 300 mg/kg) dose-dependently prevents the reduction induced by the perfusion of noradrenaline (3.5 micrograms/kg.min, 30 min) in gastric mucosal blood flow, as measured by 3H-aniline clearance. Zinc acexamate pretreatment also increases the levels of prostaglandin E2 in the gastric mucosa of the rat, both under control conditions and after infusion with noradrenaline. The levels of thromboxane A2 and prostacyclin were not modified by zinc acexamate. These results confirm the importance of microcirculation in pathogenesis and the idea tha…

Malemedicine.medical_specialtyMetabolic Clearance RateClinical BiochemistryProstacyclinBiologyMicrocirculationNorepinephrinechemistry.chemical_compoundThromboxane A2Internal medicinemedicineGastric mucosaAnimalsProstaglandin E2Chromatography High Pressure LiquidAminocaproatesStomachProstanoidRats Inbred StrainsCell BiologyAnti-Ulcer AgentsRatsEndocrinologymedicine.anatomical_structurechemistryGastric MucosaRegional Blood FlowAminocaproic AcidProstaglandinsPerfusionmedicine.drugProstaglandins, Leukotrienes and Essential Fatty Acids
researchProduct

Minimal Change Esophagitis: Prospective Comparison of Endoscopic and Histological Markers between Patients with Non-Erosive Reflux Disease and Normal…

2004

<i>Introduction:</i> More than half the patients with gastroesophageal reflux disease (GERD) show no endoscopic abnormality or minimal change esophagitis (non-erosive reflux disease, NERD). We investigated the value of endoscopic and histological markers for the prediction of NERD before and after treatment with 20 mg esomeprazole. <i>Methods:</i> Between July and October 2002, consecutive patients presenting for upper endoscopy were stratified into GERD and non-reflux patients (control group) with the help of a questionnaire. The endoscopist was blind to the presence of reflux symptoms. Using magnifying endoscopes minimal change esophagitis was defined by the presen…

Malemedicine.medical_specialtyNerdBiopsySensitivity and SpecificityGastroenterologyPredictive Value of TestsInternal medicinemedicineEsophagitisHumansProspective StudiesEnzyme Inhibitorsskin and connective tissue diseasesProspective cohort studybusiness.industrydigestive oral and skin physiologyGastroenterologyRefluxCase-control studyEsomeprazoleProton Pump InhibitorsGeneral MedicineMiddle AgedAnti-Ulcer Agentsmedicine.diseasehumanitiesdigestive system diseasesCase-Control StudiesPredictive value of testsGERDFemaleEsophagoscopysense organsAbnormalitybusinessEsophagitisDigestive Diseases
researchProduct

Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors.

2007

Antisecretory drugs are effective antiulcer agents, but its chronic use generates hypergastrinemia and accelerates the development of atrophic gastritis in Helicobacter pylori-positive patients. We have recently shown that gastrin exerts a proinflammatory effect in rats through CCK-2 receptor activation that contributes to the inflammation induced by H. pylori. The present study was designed to examine whether gastrin hypersecretion in response to treatment with antisecretory drugs induces an inflammatory response that could promote mucosal atrophy. The effects of omeprazole or famotidine on leukocyte/endothelial cell interactions in vivo were analyzed in rat mesenteric venules using intrav…

Malemedicine.medical_specialtyProglumidemedicine.drug_classInflammationCD18Cell CommunicationProinflammatory cytokineRats Sprague-DawleyInternal medicineGastrinsmedicineLeukocytesAnimalsOmeprazoleGastrinPharmacologyInflammationMicroscopy Videobusiness.industryEndothelial CellsProton Pump InhibitorsReceptor antagonistAnti-Ulcer AgentsFlow CytometryImmunohistochemistryReceptor Cholecystokinin BRatsFamotidineChemotaxis LeukocyteEndocrinologyGastric MucosaMolecular Medicinemedicine.symptombusinessmedicine.drugThe Journal of pharmacology and experimental therapeutics
researchProduct

A pharmacological approach to gastric acid inhibition.

2005

Proton pump inhibitors have changed our approach to gastric acid-related diseases. They are much more potent acid inhibitors than H2-antagonists and exhibit a sophisticated mechanism of action. The present review analyses the general pharmacology of proton pump inhibitors and differentiates the specific characteristics of the various compounds that belong to this family. Special emphasis has been placed in describing the clinical implications of such differences and the potential importance for adverse effects.

Peptic UlcerChemistrymedicine.drug_classPharmacology toxicologyProton-pump inhibitorProton Pump InhibitorsAnti-Ulcer AgentsGastric AcidBiochemistryMechanism of actionmedicineGastric acidHumansPharmacology (medical)medicine.symptomAdverse effectDrugs
researchProduct